Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jun 1;127(11):1937-1938.
doi: 10.1002/cncr.33432. Epub 2021 Mar 15.

COVID-19 in patients with hematological malignancies: Considering the role of tyrosine kinase inhibitors

Alejandro Morales-Ortega  1 , Jaime García de Tena  2 , Begoña Frutos-Pérez  1 , Beatriz Jaenes-Barrios  3 , Ana Isabel Farfán-Sedano  1 , Miguel Ángel Canales-Albendea  4 , David Bernal-Bello  1
Affiliations
Comment

COVID-19 in patients with hematological malignancies: Considering the role of tyrosine kinase inhibitors

Alejandro Morales-Ortega et al. Cancer. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Miguel Ángel Canales‐Albendea declares consulting fees from Novartis. David Bernal‐Bello is the principal investigator of a nonsponsored randomized trial investigating the therapeutic role of imatinib and baricitinib in patients with coronavirus disease 2019 (NCT04346147); Alejandro Morales‐Ortega, Begoña Frutos‐Pérez, Beatriz Jaenes‐Barrios, and Ana Isabel Farfán‐Sedano are subinvestigators of this project. The other author made no disclosures.

Comment in

Comment on

References

    1. Cattaneo C, Daffini R, Pagani C, et al. Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID‐19. Cancer. 2020;126:5069‐5076.doi:10.1002/cncr.33160 - DOI - PubMed
    1. Sisk JM, Frieman MB, Machamer CE. Coronavirus S protein–induced fusion is blocked prior to hemifusion by Abl kinase inhibitors. J Gen Virol. 2018;99:619‐630.doi:10.1099/jgv.0.001047 - DOI - PMC - PubMed
    1. Coleman CM, Sisk JM, Mingo RM, et al. Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion. J Virol. 2016;90:8924‐8933.doi:10.1128/JVI.01429-16 - DOI - PMC - PubMed
    1. Sauvat A, Ciccosanti F, Colavita F, et al. On‐target versus off‐target effects of drugs inhibiting the replication of SARS‐CoV‐2. Cell Death Dis. 2020;11:656. doi:10.1038/s41419-020-02842-x - DOI - PMC - PubMed
    1. Zhao H, Mendenhall M, Deininger MW. Imatinib is not a potent anti–SARS‐CoV‐2 drug. Leukemia. Published online September 30, 2020. doi:10.1038/s41375-020-01045-9 - DOI - PMC - PubMed

Substances